Urinary cGMP excretion after hormone replacement therapy in postmenopausal women

Experimental and Clinical Endocrinology and Diabetes

Volumn 104, Issue 5, 1996, Pages 392-395

  Mueck, A O ^a   Seeger, H ^a   Kasspohl Butz S ^b   Teichmann, A T ^b   Lippert, T H ^a,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Clinic Aschaffenburg   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Hormone replacement therapy; Postmenopausal women; Urinary cGMP excretion

Indexed keywords

CYCLIC GMP; ESTRADIOL VALERATE; NORETHISTERONE ACETATE;

ADULT; ARTICLE; BLOOD VESSEL TONE; CLINICAL ARTICLE; CLINICAL TRIAL; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; NUCLEIC ACID METABOLISM; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; URINARY EXCRETION;

EID: 0029822321     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1211473     Document Type: Article

References (17)

1. Barrett-Connor E, Bush TL: Estrogen and coronary heart disease in women. JAMA 265: 1861-1867, 1991.
2. Braselton WE, Lin TJ, Mills TM, Ellegood JO, Mahesh VB: Identification and measurement by gas chromatography-mass spectrometry of norethindrone and metabolites in human urine and blood. J Steroid Biochem 8: 9-18, 1977.
3. Broadus AE, Hardman JG, Kaminsky NI, Ball JH, Sutherland EW Liddle GW: Extracellular cyclic nucleotides. Ann NY Acad Sci 185: 50-66, 1971.
4. Hishikawa K, Nakaki T, Marumo T, Suzuki H, Kato R, Saruta T: Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Letters 360: 291-293, 1995.
5. 2+ in guinea-pig isolated cardiac myocytes. Br J Pharmacol 106: 739-45, 1992.
6. Jiang C, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P: Endothelium-independent relaxation of rabbit coronary artery by 17β-oestradiol in vitro. Br J Pharmacol 104: 1033-37, 1991.
7. Kuhl H: Hormonale Kontrazeption und Substitutionstherapie: Die Bedeutung des Gestagens für kardiovaskuläre Erkrankungen. Geburtsh. u. Frauenheilk. 52: 653-662, 1992.
8. Lippert TH, Seeger H, Mueck AO, Hanke H, Haasis R: Effect of estradiol. progesterone and progestogens on calcium influx in cell cultures of human vessels. Menopause, 3: 33-37, 1996.
9. Mueck AO, Seeger H, Korte K, Haasis R, Lippert TH: Beeinfluβt Östradiol das NO/cGMP-System der Gefäβe? Untersuchungen zum Mechanismus der kardiovaskulären Protektion durch Östrogensubstitution in der Postmenopause. Zentralbl Gynäkologie 116: 507-511, 1994.
10. Mueck AO, Seeger H, Korte K, Lippert TH: The effect of 17β-estradiol and endothelin 1 on prostacyclin and thromboxane production in human endothelial cell cultures. Clin. Exp. Obstet. Gynecol. 20: 203-206, 1993.
11. Mueck AO, Seeger H, Wiesner J, Korte K, Lippert TH: Urinary prostanoids in postmenopausal women after transdermal and oral oestrogen. J. Obstet. Gynaecology 14: 341-345, 1994.
12. Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA: Pharmacokinetics of transdermal dosage forms of 17β-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 152: 1099-1106, 1985.
13. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH: Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med 325: 756-762, 1991.
14. Stanczyk FZ, Roy S: Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception 42: 67-96, 1990.
15. 2+ up-take of uterine arterial smooth muscle cells through potential-sensitive channel. Biol Reprod 36: 361-368, 1987.
16. Vose CW, Butler JK, Williams BM, Stafford JEH, Shelton JR, Rose DA, Palmer RF, Breckenridge AM, Orme M L'E, Serlin MJ: Bioavailability and pharmacokinetics of norethisterone in women after oral doses of ethynodiol diacetate. Contraception 19: 119-122; 1979.
17. Whitehead MI, Townsend PT, Pryse-Davies, J., Ryder T, Lane G, Siddle NC, King RJB: Effect of various dosages of progestogens on the postmenopausal endometrium. J Reprod Med 27: 539-548, 1982.